keyword
MENU ▼
Read by QxMD icon Read
search

Response evaluation of solid tumors

keyword
https://www.readbyqxmd.com/read/29671876/immunotherapy-and-the-role-of-imaging
#1
REVIEW
Brett W Carter, Priya R Bhosale, Wei T Yang
Significant advances in the genetic and molecular characterization of cancer have led to the development of effective immunotherapies. These therapeutics help the host immune system recognize cancer as foreign, promote the immune system, and relieve the inhibition that allows growth and spread of tumors. Experience with various immunotherapies, particularly the immunomodulatory monoclonal antibody ipilimumab, has demonstrated that unique patterns of response may be encountered that cannot be adequately captured by traditional response criteria, such as the World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), which have been used primarily with cytotoxic chemotherapies...
April 19, 2018: Cancer
https://www.readbyqxmd.com/read/29670367/pet-ct-evaluation-of-the-curative-effect-of-crizotinib-on-malignant-myofibroblastoma-with-rare-mutation-of-alk-r401-a-case-report-and-literature-review
#2
Li Yang, Yufeng Wu, Hong Tang, Jiuzhou Zhao, Dongdong Zhao, Sen Yang, Qiming Wang
Objective: The purpose of this article is to explore the targeted treatment of malignant myofibroblastoma and evaluate the role of neoplasm metabolite markers in the evaluation of efficacy after targeted therapy. Method: This report described a case of myofibroblastic sarcoma with rare mutation of ALK R401 in a 58-year-old man prescribed with crizotinib, to evaluate its curative effect by positron emission tomography coupled with computed tomography (PET-CT). After the progressive disease in the brain, bevacizumab combined with crizotinib was administered...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29670350/colloidal-plasmonic-gold-nanoparticles-and-gold-nanorings-shape-dependent-generation-of-singlet-oxygen-and-their-performance-in-enhanced-photodynamic-cancer-therapy
#3
Yamin Yang, Yue Hu, Henry Du, Lei Ren, Hongjun Wang
Introduction: In recognition of the potentials of gold nanoparticles (Au NPs) in enhanced photodynamic therapy (PDT) for cancer, it is desirable to further understand the shape-dependent surface plasmonic resonance (SPR) properties of various gold nanostructures and evaluate their performances in PDT. Materials and methods: Monodispersed colloidal spherical solid Au NPs were synthesized by UV-assisted reduction using chloroauric acid and sodium citrate, and hollow gold nanorings (Au NRs) with similar outer diameter were synthesized based on sacrificial galvanic replacement method...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29669701/crizotinib-in-patients-with-advanced-inoperable-inflammatory-myofibroblastic-tumours-with-and-without-anaplastic-lymphoma-kinase-gene-alterations-european-organisation-for-research-and-treatment-of-cancer-90101-create-a-multicentre-single-drug-prospective-non
#4
Patrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, Jean-Yves Blay, Sandra J Strauss, Silvia Stacchiotti, Piotr Rutkowski, Lars H Lindner, Michael G Leahy, Antoine Italiano, Nicolas Isambert, Maria Debiec-Rychter, Raf Sciot, Thomas Van Cann, Sandrine Marréaud, Axelle Nzokirantevye, Sandra Collette, Agnieszka Wozniak
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK)...
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29664561/the-function-and-dysfunction-of-memory-cd8-t-cells-in-tumor-immunity
#5
REVIEW
James L Reading, Felipe Gálvez-Cancino, Charles Swanton, Alvaro Lladser, Karl S Peggs, Sergio A Quezada
The generation and maintenance of CD8+ T cell memory is crucial to long-term host survival, yet the basic tenets of CD8+ T cell immunity are still being established. Recent work has led to the discovery of tissue-resident memory cells and refined our understanding of the transcriptional and epigenetic basis of CD8+ T cell differentiation and dysregulation. In parallel, the unprecedented clinical success of immunotherapy has galvanized an intense, global research effort to decipher and de-repress the anti-tumor response...
May 2018: Immunological Reviews
https://www.readbyqxmd.com/read/29660598/first-in-human-phase-1-dose-escalation-pharmacokinetic-and-pharmacodynamic-study-of-the-oral-dual-pi3k-and-mtorc1-2-inhibitor-pqr309-in-patients-with-advanced-solid-tumors-sakk-67-13
#6
Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, Vincent Bize, Hanne Hawle, Simona Berardi, Nataša Cmiljanović, Vladimir Cmiljanović, Michael Stumm, Saša Dimitrijević, Richard Herrmann, Vincent Prêtre, Reto Ritschard, Alexandar Tzankov, Viviane Hess, Alexa Childs, Cinta Hierro, Jordi Rodon, Dagmar Hess, Markus Joerger, Roger von Moos, Cristiana Sessa, Rebecca Kristeleit
BACKGROUND: PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor. PATIENTS AND METHODS: This is an accelerated titration, 3 + 3 dose-escalation, open-label phase I trial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumours. Primary objectives were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)...
April 13, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29659611/preoperative-evaluation-of-the-efficacy-of-radio-hyperthermo-chemotherapy-for-soft-tissue-sarcoma-in-a-case-series
#7
Hisaki Aiba, Satoshi Yamada, Jun Mizutani, Norio Yamamoto, Hideki Okamoto, Katsuhiro Hayashi, Hiroaki Kimura, Akihiko Takeuchi, Shinji Miwa, Takashi Higuchi, Kensaku Abe, Yuta Taniguchi, Yoshihiro Araki, Hiroyuki Tsuchiya, Takanobu Otsuka
PURPOSE: Radio-hyperthermo-chemo (RHC) therapy, which combines radiotherapy, hyperthermia, and chemotherapy, for malignant soft tissue tumors has been introduced with the aim of decreasing the possibility of local recurrence after surgery. To avoid unnecessary neoadjuvant therapy and to plan the appropriate surgical treatment, surveillance of RHC therapeutic efficacy during treatment is necessary. In this study, we determined the optimal response criteria to evaluate the efficacy of RHC by comparing preoperative images before and after RHC with pathological evaluation of necrosis in the resected tumor...
2018: PloS One
https://www.readbyqxmd.com/read/29656632/long-term-survival-in-patients-treated-with-a-robotic-radiosurgical-device-for-liver-metastases
#8
Sebastian Stintzing, Jobst von Einem, Christoph Fueweger, Alfred Haidenberger, Michael Fedorov, Alexander Muavcevic
Purpose: The treatment of liver metastases with local procedures is a fast progressing field. For the most, long-term survival data is missing raising questions with regard to the efficacy of such modalities when compared to surgical resection. Radiosurgery using the CyberKnife device enables the treatment of liver lesions with a single-session approach. Here we present long-term survival data to explore the curative potential of this strategy. Materials and Methods: Patients with oligo-metastatic disease limited to the liver have been treated with single-session or hypo-fractioned radiosurgery in curative intent and prospectively followed until death...
April 16, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29645065/-131-i-mibg-therapy-of-malignant-pheochromocytoma-and-paraganglioma-tumors-a-single-center-study
#9
Agnieszka Kotecka-Blicharz, Kornelia Hasse-Lazar, Daria Handkiewicz-Junak, Tomasz Gawlik, Agnieszka Pawlaczek, Małgorzata Oczko-Wojciechowska, Barbara Michalik, Sylwia Szpak-Ulczok, Jolanta Krajewska, Beata Jurecka-Lubieniecka, Barbara Jarząb
INTRODUCTION: Pheochromocytomas and paragangliomas are rare tumors deriving from chromaffin cells of adrenal medulla or paraganglia. They are usually benign but 10-35% of them present malignant behavior. The aim of the study was to evaluate the efficacy and safety of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL). MATERIAL AND METHODS: 18 patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 131-I MIBG therapy because of MPPGL and their medical data were analyzed retrospectively...
April 12, 2018: Endokrynologia Polska
https://www.readbyqxmd.com/read/29629795/mri-detection-of-intratumoral-fat-in-colorectal-liver-metastases-after-preoperative-chemotherapy
#10
Yudai Nakai, Wataru Gonoi, Akifumi Hagiwara, Yujiro Nishioka, Hiroyuki Abe, Junichi Shindoh, Kiyoshi Hasegawa
OBJECTIVE: The objective of this study was to investigate the incidence and clinical significance of intratumoral fat deposition in colorectal liver metastases (CLMs) after preoperative chemotherapy using dual-echo gradient-recalled echo MRI. MATERIALS AND METHODS: Our institutional review board approved this retrospective radiographic study and waived the requirement for informed patient consent. Fifty-nine patients (33 men, 26 women; median age, 62 years old) who underwent preoperative MRI and curative hepatic resection for colorectal liver metastases after chemotherapy were selected...
April 9, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29627288/multiparametric-whole-body-mri-with-diffusion-weighted-imaging-and-adc-mapping-for-the-identification-of-visceral-and-osseous-metastases-from-solid-tumors
#11
Michael A Jacobs, Katarzyna J Macura, Atif Zaheer, Emmanuel S Antonarakis, Vered Stearns, Antonio C Wolff, Thorsten Feiweier, Ihab R Kamel, Richard L Wahl, Li Pan
RATIONALE AND OBJECTIVES: The purpose of this study was to investigate the use of multiparametric, whole-body, diffusion-weighted imaging (WB-DWI) and apparent diffusion coefficient (ADC) maps with T2 -weighted magnetic resonance imaging (MRI) at 3T for the detection and monitoring of metastatic disease in patients. MATERIALS AND METHODS: Fifty-four participants (32 healthy subjects and 22 patients) were scanned with WB-DWI methods using a 3T MRI scanner. Axial, sagittal, or coronal fat-suppressed T2 -weighted (T2 WI), T1 -weighted (T1 WI), and DWI images were acquired...
April 4, 2018: Academic Radiology
https://www.readbyqxmd.com/read/29618578/pet-response-assessment-in-apatinib-treated-radioactive-iodine-refractory-thyroid-cancer
#12
Chen Wang, Xin Zhang, Xue Yang, Hui Li, Ruixue Cui, Wenmin Guan, Xin Li, Zhaohui Zhu, Yansong Lin
This work evaluated the use of the positron emission tomography/computed tomography (PET/CT) technique to assess the early therapeutic response and predict the prognosis of patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) who underwent apatinib therapy. Standardised uptake value (SUV), metabolic tumour volume (MTV) and total lesion glycolysis (TLG), derived from 18FDG PET/CT and SUV from 68Ga-NOTA-PRGD2 PET/CT, were evaluated. Tumour response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) 1...
April 4, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29615295/radiologic-and-pathologic-response-to-neoadjuvant-chemotherapy-predicts-survival-in-patients-undergoing-the-liver-first-approach-for-synchronous-colorectal-liver-metastases
#13
Giammauro Berardi, Marc De Man, Stéphanie Laurent, Peter Smeets, Federico Tomassini, Riccardo Ariotti, Anne Hoorens, Jo van Dorpe, Oswald Varin, Karen Geboes, Roberto I Troisi
PURPOSE: To investigate the short- and long-term outcomes of liver first approach (LFA) in patients with synchronous colorectal liver metastases (CRLM), evaluating the predictive factors of survival. METHODS: Sixty-two out of 301 patients presenting with synchronous CRLM underwent LFA between 2007 and 2016. All patients underwent neoadjuvant chemotherapy. After neoadjuvant treatment patients were re-evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST)...
March 21, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29613988/dual-energy-computed-tomography-based-iodine-quantitation-for-response-evaluation-of-lung-cancers-to-chemoradiotherapy-radiotherapy-a-comparison-with-fluorine-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-based-positron-emission-tomography
#14
Yanping Ren, Yuxin Jiao, Weiqiang Ge, Libo Zhang, Yanqing Hua, Cheng Li, Weihao Zhai, Xi Tang, Wei He, Min Fang, Xiangpeng Zheng
OBJECTIVE: The objective of this study was to investigate the correlation between dual-energy computed tomography (DECT)-based iodine quantitation and fluorine-18 fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging for response evaluation of lung cancers to treatment. METHODS: In this prospective study, a total of 32 pairs of DECT and F-FDG PET/CT imaging acquired consecutively from 13 patients with primary or metastatic lung cancers receiving either radiotherapy alone or chemoradiotherapy were analyzed...
April 2, 2018: Journal of Computer Assisted Tomography
https://www.readbyqxmd.com/read/29611022/a-phase-i-open-label-two-stage-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-the-oral-akt-inhibitor-gsk2141795-in-patients-with-solid-tumors
#15
Carol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, Lillian L Siu, Lee-Ann Stayner, Jennifer J Wheler, David S Hong, Carla Kurkjian, Shubham Pant, Ademi Santiago-Walker, Jennifer L Gauvin, Joyce M Antal, Joanna B Opalinska, Shannon R Morris, Jeffrey R Infante
Background We sought to determine the recommended phase II dose (RP2D) and schedule of GSK2141795, an oral pan-AKT kinase inhibitor. Patients and Methods Patients with solid tumors were enrolled in the dose-escalation phase. Pharmacokinetic (PK) analysis after a single dose (Cycle 0) informed dose escalation using accelerated dose titration. Once one grade 2 toxicity or dose-limiting toxicity was observed in Cycle 1, the accelerated dose titration was terminated and a 3 + 3 dose escalation was started. Continuous daily dosing was evaluated along with two intermittent regimens (7 days on/7 days off and 3 times per week)...
April 3, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29606586/larotrectinib-for-paediatric-solid-tumours-harbouring-ntrk-gene-fusions-phase-1-results-from-a-multicentre-open-label-phase-1-2-study
#16
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco, Brian B Tuch, Kevin T Ebata, Mark Reynolds, Steven Smith, Scott Cruickshank, Michael C Cox, Alberto S Pappo, Douglas S Hawkins
BACKGROUND: Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients. METHODS: This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion status; had a Karnofsky (≥16 years of age) or Lansky (<16 years of age) performance status score of 50 or more, adequate organ function, and full recovery from the acute toxic effects of all previous anticancer therapy...
March 29, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29606140/identification-of-immunologic-and-clinical-characteristics-that-predict-inflammatory-response-to-c-novyi-nt-bacteriolytic-immunotherapy
#17
Amy E DeClue, Sandra M Axiak-Bechtel, Yan Zhang, Saurabh Saha, Linping Zhang, David D Tung, Jeffrey N Bryan
BACKGROUND: Clostridium novyi-NT (CNV-NT), has shown promise as a bacterolytic therapy for solid tumors in mouse models and in dogs with naturally developing neoplasia. Factors that impact the immunologic response to therapy are largely unknown. The goal of this pilot study was to determine if plasma immune biomarkers, immune cell function, peripheral blood cytological composition and tumor characteristics including evaluation of a PET imaging surrogate of tumor tissue hypoxia could predict which dogs with naturally developing naïve neoplasia would develop an inflammatory response to CNV-NT...
April 2, 2018: BMC Veterinary Research
https://www.readbyqxmd.com/read/29604231/reframing-the-approach-to-patients-with-hepatocellular-carcinoma-longitudinal-assessment-with-halthcc-improves-ablate-and-wait-strategy
#18
Daniel J Firl, Shoko Kimura, John McVey, Koji Hashimoto, Heidi Yeh, Charles M Miller, James F Markmann, Kazunari Sasaki, Federico N Aucejo
Patients with hepatocellular carcinoma (HCC) are screened at presentation for appropriateness of liver transplantation (LT) using morphometric criteria, which poorly specifies risk. Morphology is the crux of measuring tumor response to locoregional therapy (LRT) using modified response evaluation criteria in solid tumors (mRECIST). This study investigated the utility of following a continuous risk score (hazard associated with liver transplantation in HCC [HALTHCC]) to longitudinally assess risk. This multicenter retrospective study from 2002-2014 enrolled 419 patients listed for LT for HCC...
March 31, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29602973/sunitinib-shrinks-net-g3-pancreatic-neuroendocrine-neoplasms
#19
Yuki Mizuno, Atsushi Kudo, Takumi Akashi, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Hiroaki Ono, Yusuke Mitsunori, Daisuke Ban, Shinji Tanaka, Ukihide Tateishi, Minoru Tanabe
PURPOSE: The 2017 revised World Health Organization classification of pancreatic neuroendocrine neoplasms classified conventional G3 tumors into well-differentiated (NET-G3) and poorly differentiated (NEC-G3) tumors. However, guidelines for selection of drug therapy were not established in the 2017 revision. This study aimed to elucidate the rates of maximum tumor reduction of sunitinib, progression-free survival, and overall survival in the new classification. METHODS: We investigated the reduction rate over time using computed tomography for 60 patients with unresectable or distant metastatic pancreatic neuroendocrine neoplasms who received 37...
March 30, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29602726/does-enhancement-or-perfusion-on-preprocedure-ct-predict-outcomes-after-embolization-of-hepatocellular-carcinoma
#20
Alessandra Borgheresi, Adrian Gonzalez-Aguirre, Karen T Brown, George I Getrajdman, Joseph P Erinjeri, Anne Covey, Hooman Yarmohammadi, Etay Ziv, Constantinos T Sofocleous, Franz Edward Boas
RATIONALE AND OBJECTIVE: The objective of this study was to evaluate whether quantitative enhancement or perfusion measurements on preprocedure triphasic computed tomography (CT) can be used to predict response or overall survival after embolization of hepatocellular carcinoma. MATERIALS AND METHODS: The institutional review board approved this retrospective review of 63 patients with hepatocellular carcinoma treated with particle embolization between March 2009 and December 2014...
March 27, 2018: Academic Radiology
keyword
keyword
32393
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"